{
  "id": "resp_0e184e74a8bc224000693c9001480c81948e63a4f131618c8c",
  "object": "response",
  "created_at": 1765576705,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_0e184e74a8bc224000693c9001b8188194a10365577bd19daf",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e184e74a8bc224000693c9002f3d4819493f3acaac87422f0",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "EudraCT CDK12/13 inhibitor triple negative breast cancer"
      }
    },
    {
      "id": "rs_0e184e74a8bc224000693c9004a4808194918c64fd90d96ace",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e184e74a8bc224000693c9006b6188194aa1e388f32086fe7",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "EudraCT dinaciclib triple negative breast cancer"
      }
    },
    {
      "id": "rs_0e184e74a8bc224000693c90085ecc8194ac4e2f895328ddd7",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e184e74a8bc224000693c900a6a3481949384ba9af2cb62df",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CT7439 EudraCT"
      }
    },
    {
      "id": "rs_0e184e74a8bc224000693c900c738881949760ca434800755d",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e184e74a8bc224000693c900d849881949ea47755c81658d6",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
      }
    },
    {
      "id": "rs_0e184e74a8bc224000693c900e5ebc8194ba1a5a30df5ec760",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e184e74a8bc224000693c900fa3688194b9711f544be14df4",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "NCT06600789 EudraCT"
      }
    },
    {
      "id": "rs_0e184e74a8bc224000693c9011fbc08194b9336ed8733a2ae0",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e184e74a8bc224000693c901645e881948a74b45529529ea2",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "\"EudraCT\" dinaciclib epirubicin"
      }
    },
    {
      "id": "rs_0e184e74a8bc224000693c9019d738819481442a0d42bf6843",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e184e74a8bc224000693c901f4a648194be791eb2a55add99",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrialsregister.eu dinaciclib epirubicin breast EudraCT"
      }
    },
    {
      "id": "rs_0e184e74a8bc224000693c90239dc881948dd3befb5802aaff",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e184e74a8bc224000693c9032d01c81949af2bdfb53ed1371",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
      }
    },
    {
      "id": "rs_0e184e74a8bc224000693c9034b3988194901958d4fa59931c",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e184e74a8bc224000693c9036958081949217f66d6d420792",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7808100/"
      }
    },
    {
      "id": "rs_0e184e74a8bc224000693c90395720819485a04bbc2733b3b6",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e184e74a8bc224000693c903c8e8c8194b679dffb782b1fcb",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "THZ531",
        "url": "https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-023-01648-x"
      }
    },
    {
      "id": "rs_0e184e74a8bc224000693c903f02ac8194bfa16b7cdb3bf518",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0e184e74a8bc224000693c9040297481949d4a7fb07ae2c7e0",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "2012-003505-10",
        "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7808100/"
      }
    },
    {
      "id": "rs_0e184e74a8bc224000693c9041eaec8194bb5774a92fee0bba",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_0e184e74a8bc224000693c90601b408194996e8b53b90c5203",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [],
          "logprobs": [],
          "text": "- **Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed** — `https://pubmed.ncbi.nlm.nih.gov/31668947/`\n  - “Here we report the development of **SR-4835**, a highly selective dual inhibitor of **CDK12** and **CDK13**, which disables triple-negative breast cancer (**TNBC**) cells.”\n  - “Keywords:  **BRCAness**; **CDK12**; **CDK13**; **PARP inhibitor**; **cisplatin**; intronic polyadenylation; triple-negative breast cancer.”\n\n- **Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors | Breast Cancer Research** — `https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-023-01648-x`\n  - “These studies have raised interest in combining these inhibitors, including **CDK12/13 inhibitor THZ531**, with a variety of other anti-cancer agents.”\n  - “Kinase inhibitor combination screenings were performed to identify kinase inhibitors that synergize with **CDK7 inhibitor THZ1** and **CDK12/13 inhibitor THZ531** in **TNBC** cell lines.”\n\n- **Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor)** — `https://www.carricktherapeutics.com/news-media/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase`\n  - “the Phase 1 clinical trial evaluating **CT7439**, a novel cyclin dependent kinase 12/13 (**CDK12/13**) inhibitor / **Cyclin-K glue-degrader**.”\n  - “Clinical trial details can also be found on www.clinicaltrials.gov under study ID: **NCT06600789**.”\n\n- **CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer - PubMed** — `https://pubmed.ncbi.nlm.nih.gov/38574883/`\n  - “Two CDK-inhibitors (CDKi), the broad range **dinaciclib** and the **CDK12-specific SR-4835**, strongly reduced the expression of key HR genes…”\n  - “Consequently, both CDKis showed synergism with **olaparib**, as well as with **cisplatin** and **gemcitabine**, in a range of **TNBC** cell lines…”\n\n- **Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer - PubMed** — `https://pubmed.ncbi.nlm.nih.gov/32471999/`\n  - “within a phase 2 window clinical trial, **RIO trial (EudraCT 2014-003319-12)**, we investigate the activity of **PARP inhibitors** in 43 patients with untreated **TNBC**.”\n  - “Following **rucaparib** treatment there was no association of Ki67 change with HR deficiency.”\n\n- **Phase II study of eribulin in combination with gemcitabine… (ERIGE trial) - PMC** — `https://pmc.ncbi.nlm.nih.gov/articles/PMC7808100/`\n  - “patients with locally advanced BC or **TNBC (ERIGE trial; EudraCT number: 2012-003505-10)**.”\n  - “### EudraCT number  **2012-003505-10**.”"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 49430,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 5627,
    "output_tokens_details": {
      "reasoning_tokens": 4842
    },
    "total_tokens": 55057
  },
  "user": null,
  "metadata": {}
}